Single dose ciprofloxacin for treating gonococcal infections in men

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Gonorrhea, caused by Neisseria gonorrhoeae, is a common sexually transmitted infection.
• Penicillinase-producing Neisseria gonorrhoeae (PPNG) strains pose treatment challenges.
• Coinfection with Chlamydia trachomatis is frequent in patients with gonorrhea.

Purpose of the Study:

• To evaluate the efficacy of a single oral dose of ciprofloxacin in treating gonorrhea.
• To assess the effectiveness of ciprofloxacin against Chlamydia trachomatis.
• To monitor for adverse effects, including liver function abnormalities.

Main Methods:

• A single oral dose of 500 mg or 250 mg of ciprofloxacin was administered to men with gonococcal infections.
• Patients with gonococcal urethritis, proctitis, and pharyngitis were included.
• Urethral specimens were tested for Neisseria gonorrhoeae and Chlamydia trachomatis before and after treatment.
• Liver function tests were performed post-treatment in the 250 mg group.

Main Results:

• All patients treated with 500 mg or 250 mg of ciprofloxacin were cured of gonococcal infections.
• Ciprofloxacin was ineffective against Chlamydia trachomatis, with reinfection or persistent infection observed.
• Four penicillinase-producing strains of Neisseria gonorrhoeae were successfully treated.
• 11% of patients receiving 250 mg ciprofloxacin showed minor liver function abnormalities.

Conclusions:

• A single oral dose of ciprofloxacin is an effective treatment for uncomplicated gonorrhea, including infections with penicillinase-producing strains.
• Ciprofloxacin does not effectively treat Chlamydia trachomatis coinfections.
• Further monitoring for liver function is advised in patients treated with ciprofloxacin.